Theravance splits into dividend and growth companies

Theravance CEO Rick Winningham said the South San Francisco-based biopharmaceutical business is not splitting into two separate publicly-traded companies just because it could not find a buyer for its mix of registration-phase respiratory therapies – Breo and Anoro for chronic obstructive pulmonary disease (COPD) – and development-stage assets.